UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview

Biochemical Society transactions, 2016-06, Vol.44 (3), p.951-959

2016

Volltextzugriff (PDF)

CD4+ T-cell alloreactivity after haploidentical hematopoietic stem cell transplantation

Haematologica (Roma), 2021-02, Vol.106 (2), p.585-588

2021

Volltextzugriff (PDF)

Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors

Cancer, 2012-12, Vol.118 (23), p.6005-6011

2012

Volltextzugriff (PDF)

Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells

Clinical immunology (Orlando, Fla.), 2016-08, Vol.169, p.107-113

2016

Volltextzugriff (PDF)

Double Umbilical Cord Blood Transplantation in High‐Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance

HemaSphere, 2019-10, Vol.3 (5), p.1-4

2019

Volltextzugriff (PDF)

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Molecular therapy, 2013-04, Vol.21 (4), p.904-912

2013

Volltextzugriff (PDF)

Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells

Cytotherapy (Oxford, England), 2013-05, Vol.15 (5), p.620-626

2013

Volltextzugriff (PDF)

Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells

Blood, 2011-01, Vol.117 (1), p.72-82

2011

Volltextzugriff (PDF)

T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk

Clinical cancer research, 2017-10, Vol.23 (20), p.6012-6020

2017

Volltextzugriff (PDF)

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies

Clinical cancer research, 2022-04, Vol.28 (8), p.1572-1585

2022

Volltextzugriff (PDF)

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

Journal of clinical oncology, 2006-05, Vol.24 (13), p.e20-e22

2006

Volltextzugriff (PDF)

Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials

Clinical cancer research, 2010-12, Vol.16 (23), p.5852-5861

2010

Volltextzugriff (PDF)

CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation

Blood, 2016-10, Vol.128 (17), p.2165-2174

2016

Volltextzugriff (PDF)

Inflammation and Fatigue Dimensions in Advanced Cancer Patients and Cancer Survivors: An Explorative Study

Cancer, 2012-12, Vol.118 (23), p.6005-6011

2012

Volltextzugriff (PDF)

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients

Frontiers in immunology, 2016-12, Vol.7, p.648-648

2016

Volltextzugriff (PDF)

Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors

Clinical cancer research, 2014-09, Vol.20 (18), p.4776-4783

2014

Volltextzugriff (PDF)

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS

Frontiers in immunology, 2018-09, Vol.9, p.2034-2034

2018

Volltextzugriff (PDF)

Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo

Cancer Immunology, Immunotherapy, 2007-12, Vol.56 (12), p.1875-1883

2007

Volltextzugriff (PDF)

Tetramer-based quantification of cytomegalovirus (CMV)–specific CD8+ T lymphocytes in T-cell–depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

Blood, 2001-09, Vol.98 (5), p.1358-1364

2001

Volltextzugriff (PDF)

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e001607

2020

Volltextzugriff (PDF)

T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness

Human gene therapy. Part B. Methods, 2014-12, Vol.25 (6), p.345-357

2014

Volltextzugriff (PDF)

mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells

Thrombosis and haemostasis, 2010-08, Vol.104 (2), p.318-326

2010

Volltextzugriff (PDF)

Quantification of circulating endothelial cells by flow cytometry

Clinical cancer research, 2009-05, Vol.15 (10), p.3640; author reply 3640-3640

2009

Volltextzugriff (PDF)

Repeated Administrations of Interleukin (IL)-12 Are Associated with Persistently Elevated Plasma Levels of IL-10 and Declining IFN-γ, Tumor Necrosis Factor-α, IL-6, and IL-8 Responses

Clinical cancer research, 2003-01, Vol.9 (1), p.76-83

2003

Volltextzugriff (PDF)

Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies

Neuro-oncology (Charlottesville, Va.), 2012-07, Vol.14 (7), p.841-848

2012

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview

CD4+ T-cell alloreactivity after haploidentical hematopoietic stem cell transplantation

Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors

Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells

Double Umbilical Cord Blood Transplantation in High‐Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells

Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells

T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials

CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation

Inflammation and Fatigue Dimensions in Advanced Cancer Patients and Cancer Survivors: An Explorative Study

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients

Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS

Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo

Tetramer-based quantification of cytomegalovirus (CMV)–specific CD8+ T lymphocytes in T-cell–depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer

T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness

mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells

Quantification of circulating endothelial cells by flow cytometry

Repeated Administrations of Interleukin (IL)-12 Are Associated with Persistently Elevated Plasma Levels of IL-10 and Declining IFN-γ, Tumor Necrosis Factor-α, IL-6, and IL-8 Responses

Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies

Suchergebnisse filtern